⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14011249 | 1.00 | — | — | |
| SCHEMBL104132 | 0.97 | — | — | |
| SCHEMBL12037552 | 0.91 | — | — | |
| SCHEMBL436990 | 0.88 | — | — | |
| SCHEMBL11456146 | 0.81 | — | — | |
| SCHEMBL13622549 | 0.80 | — | — | |
| SCHEMBL13622550 | 0.80 | — | — | |
| SCHEMBL7533125 | 0.79 | — | — | |
| SCHEMBL19347272 | 0.78 | — | — | |
| SCHEMBL13622545 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130516-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-04-27 | — | — | US | disclosed |
| US-20220213107-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| US-8334378-B2 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100291034-A1 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-7772178-B2 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070258947-A1 | Depeptidized Inhibitors of Hepatitis C Virus NS3 Protease | SCHERING CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | SCHERING CORPORATION | 2007-10-11 | — | — | US | disclosed |
| US-20070232527-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-09-06 | — | — | US | disclosed |
| US-7253160-B2 | Depeptidized inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| US-4049661-A | FIBER-REACTIVE | CIBA-GEIGY AG (CH) | 1977-09-20 | — | — | US | disclosed |